The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists
Mandala, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shei, G.-J., Card, D., Keohane, C., et al. (2002) · Science · doi:10.1126/science.1070238 · Cited by 1,690
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors
Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200176200 · Cited by 1,504
Self-citationOral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
Kappos, L., Antel, J., Comi, G., Montalban, X., O'Connor, P., Polman, C. H., Haas, T., Korn, A. A., Karlsson, G., & Radue, E. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052643 · Cited by 1,054
Lysophospholipid Receptors: Signaling and Biology
Ishii, I., Fukushima, N., Ye, X., & Chun, J. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073731 · Cited by 771
Astrocytes promote myelination in response to electrical impulses
Ishibashi, T., Dakin, K. A., Stevens, B., Lee, P. R., Kozlov, S. V., Stewart, C. L., & Fields, R. D. (2006) · Neuron · doi:10.1016/j.neuron.2006.02.006 · Cited by 689
Mice Deficient in Sphingosine Kinase 1 Are Rendered Lymphopenic by FTY720
Allende, M. L., Sasaki, T., Kawai, H., Olivera, A., Mi, Y., van Echten-Deckert, G., Hajdu, R., Rosenbach, M., Keohane, C. A., Mandala, S., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406512200 · Cited by 447
Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases
Billich, A., Bornancin, F., Dévay, P., Mechtcheriakova, D., Urtz, N., & Baumruker, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307687200 · Cited by 433
Self-citationLo, C. G., Xu, Y., Proia, R. L., & Cyster, J. G. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041509 · Cited by 319
Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment
Fujino, M., Funeshima, N., Kitazawa, Y., Kimura, H., Amemiya, H., Suzuki, S., & Li, X.-K. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045658 · Cited by 280
Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720
Zemann, B., Kinzel, B., Müller, M., Reuschel, R., Mechtcheriakova, D., Urtz, N., Bornancin, F., Baumruker, T., & Billich, A. (2006) · Blood · doi:10.1182/blood-2005-07-2628 · Cited by 264
Self-citationWebb, M., Tham, C.-S., Lin, F.-F., Lariosa-Willingham, K., Yu, N., Hale, J., Mandala, S., Chun, J., & Rao, T. S. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.04.015 · Cited by 226
Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism
Kabashima, K., Haynes, N. M., Xu, Y., Nutt, S. L., Allende, M. L., Proia, R. L., & Cyster, J. G. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061289 · Cited by 220
Kataoka, H., Sugahara, K., Shimano, K., Teshima, K., Koyama, M., Fukunari, A., & Chiba, K. (2005) · PubMed · Cited by 216
Sphingosine Kinase 2 Is Required for Modulation of Lymphocyte Traffic by FTY720
Kharel, Y., Lee, S., Snyder, A. H., Sheasley-O'Neill, S. L., Morris, M. A., Setiady, Y., Zhu, R., Zigler, M. A., Burcin, T. L., Ley, K., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506293200 · Cited by 210
Talbott, J. F., Loy, D. N., Liu, Y., Qiu, M. S., Bunge, M. B., Rao, M. S., & Whittemore, S. R. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.05.038 · Cited by 194
Toman, R. E., Payne, S. G., Watterson, K. R., Maceyka, M., Lee, N. H., Milstien, S., Bigbee, J. W., & Spiegel, S. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200402016 · Cited by 173
Daniel, C., Sartory, N., Zahn, N., Geisslinger, G., Radeke, H. H., & Stein, J. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2458 · Cited by 165
Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells
Jung, C., Kim, H., Miron, V. E., Cook, S. P., Kennedy, T. E., Foster, C. A., Antel, J. P., & Soliven, B. C. (2007) · Glia · doi:10.1002/glia.20576 · Cited by 158
Self-citationBalatoni, B., Storch, M. K., Swoboda, E.-M., Schönborn, V., Koziel, A., Lambrou, G. N., Hiestand, P. C., Weissert, R., & Foster, C. A. (2007) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2007.06.023 · Cited by 158
Self-citationPayne, S. G., Oskeritzian, C. A., Griffiths, R., Subramanian, P., Barbour, S. E., Chalfant, C. E., Milstien, S., & Spiegel, S. (2006) · Blood · doi:10.1182/blood-2006-03-011437 · Cited by 146
Kohm, A. P., Williams, J. S., Bickford, A. L., McMahon, J. S., Chatenoud, L., Bach, J., Bluestone, J. A., & Miller, S. D. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4525 · Cited by 145
Microglial activation state and lysophospholipid acid receptor expression
Tham, C., Lin, F., Rao, T. S., Yu, N., & Webb, M. (2003) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2003.09.003 · Cited by 131
Yu, N., Lariosa-Willingham, K. D., Lin, F., Webb, M., & Rao, T. S. (2003) · Glia · doi:10.1002/glia.10297 · Cited by 124
Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors
Osinde, M., Müllershausen, F., & Dev, K. K. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.11.010 · Cited by 122
Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS
Terai, K., Soga, T., Takahashi, M. P., Kamohara, M., Ohno, K., Yatsugi, S., Okada, M., & Yamaguchi, T. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00791-1 · Cited by 102
Meno‐Tetang, G. M. L., & Lowe, P. J. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960307.x · Cited by 99
Baumruker, T., Billich, A., & Brinkmann, V. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.3.283 · Cited by 94
Self-citationRao, T. S., Lariosa-Willingham, K. D., Lin, F., Palfreyman, E. L., Yu, N., Chun, J. J. M., & Webb, M. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03527-3 · Cited by 94
FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression
Brinkmann, V., Chen, S., Feng, L., Pinschewer, D. D., Nikolova, Z. G., & Hof, R. (2001) · Transplantation Proceedings · doi:10.1016/s0041-1345(00)02126-6 · Cited by 90
S1P inhibits gap junctions in astrocytes: involvement of Giand Rho GTPase/ROCK
Rouach, N., Pébay, A., Même, W., Cordier, J., Ezan, P., Etienne, E., Giaume, C., & Tencé, M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04671.x · Cited by 87
A simple method for the quantitation of 14C-whole-body autoradiograms
Schweitzer, A., Fahr, A., & Niederberger, W. (1987) · International Journal of Radiation Applications and Instrumentation Part A Applied Radiation and Isotopes · doi:10.1016/0883-2889(87)90019-0 · Cited by 44
Self-citationHabicht, A., Clarkson, M., Yang, J., Henderson, J., Brinkmann, V., Fernandes, S. M., Jurewicz, M. M., Yuan, X., & Sayegh, M. H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.36 · Cited by 38
Cited by
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Self-citationMechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796
Metadata
- Authors
- Foster, C. A., Howard, L. M., Schweitzer, A., Persohn, E., Hiestand, P. C., Balatoni, B., Reuschel, R., Beerli, C., Schwartz, M., & Billich, A.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2007-11
- Volume
- 323
- Issue
- 2
- Pages
- 469-476
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2007541166
- Cited by
- 322
- References
- 34
- FWCI
- 10.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.